San Francisco, California–(Newsfile Corp. – December 25, 2024) – On December 9, 2024, just a few months after conducting an initial public offering in September 2024, BioAge Labs, Inc. (NASDAQ: BIOA) made the surprise announcement that it was halting a Phase 2 study for its lead product, azelaprag, intended to treat metabolic diseases such as obesity.

Hagens Berman opened an investigation and urged BioAge investors who bought shares in the company’s IPO or in the open market and suffered large losses to submit your losses now.

Visit: www.hbsslaw.com/investor-fraud/bioa
Contact The Firm Today: [email protected]
844-916-0895

BioAge Labs, Inc. (BIOA) investigation:

The investigation focused on the propriety of BioAge’s disclosures about safety data and other matters related to azelaprag, which the company said in its IPO documents “well tolerated 265 individuals in eight Phase 1 clinical trials.”

BioAge’s disclosures came into question after the market closed on December 6, 2024, when the company announced the discontinuation of the STRIDES Phase 2 clinical trial evaluating azelaprag in combination with tirzepatide for the treatment of obesity. BioAge says liver transaminitis has been observed in patients receiving azelaprag.

This news brought BioAge’s share price up nearly 80% on December 9, 2024.

“We are focused on whether BioAge was transparent with investors about the safety profile of azelaprag before the December 6 announcement,” said Reed Kathrein, the Hagens Berman partner who led the investigation.

If you invested in BioAge and had significant losses, or have knowledge that could help the company’s investigation, submit your losses now »

If you would like more information and answers to frequently asked questions about the BioAge investigation, read more »

Whistleblowers: People with non-public information about BioAge should consider their options for assisting in the investigation or taking advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information can receive rewards of up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

##

About Hagens Berman
Hagens Berman is a global plaintiffs complex litigation firm focusing on corporate liability. The firm is home to a strong practice and represents investors as well as whistleblowers, workers, consumers and others in cases that achieve real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of ​​law. More about the firm and its achievements can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

To view the original version of this press release, please visit https://www.newsfilecorp.com/release/235182